Gilead Reports 61 Clinical Programs Under Way, With Over 20 In Phase III
Excluding Veklury, Core Product Sales Grow
Executive Summary
Excluding sales declines due to Veklury, Gilead said its year-over-year sales grew 15% in the first quarter, with HIV drug Biktarvy serving as the biggest driver.